Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era
ConclusionsBSI causes high mortality in patients with HNC and is most often secondary to pneumonia. It occurs mainly among patients with hypoalbuminemia who receive treatment with cetuximab or chemotherapy. The development of BSI in patients with HNC impairs their outcome, especially in the presence of hypoalbuminemia and comorbidities.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Epidemiology | Erbitux | Gastroenteritis | Head and Neck Cancer | Microbiology | Oropharyngeal Cancer | Pneumonia | Study